Advertisement
Advertisement

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Haemostasis, vascular biology, and infectious agents - Thrombophilia and anticoaulant pathway

DOI: http://dx.doi.org/10.1160/TH07-04-0272
Issue: 2007: 98/3 (Sep) pp. 483-704
Pages: 662-669

A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis

Gemma Vilahur, Laura Casaní, Lina Badimon
Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau (UAB), Barcelona, Spain

Keywords

thrombosis, thromboxane, stents, aspirin plus clopidogrel

Summary

Acute thrombosis is a threat in patients undergoing percutaneous coronary intervention with stent implantation. Our objective was to determine if stent-induced thrombus formation could be inhibited by oral treatment with a thromboxane A2/prostaglandin H2 receptor antagonist (TPr; S18886) as an alternative to standard therapy. Pigs were allocated in the following treatment (p.o) groups: I) clopidogrel (CLOP); II) ASA; III) S18886; IV) ASA+CLOP; and V) placebo-control. Damaged vessel was placed in the Badimon chamber containing a stent and perfused at 212/s.Antithrombotic effects were assessed as 111In-platelet deposition (PD) in two series (60 and 180 min after drug intake). Fibrin(ogen) deposition, light transmittance aggregometry (LTA; collagen, U46619, and ADP), and bleeding time (BT) were also evaluated. After 60 min S18886 reduced PD ≤48%, 40%, and 35% vs placebo, CLOP-, and ASA-treated animals, respectively (P<0.05), while ASA+CLOP showed a 58% reduction versus placebo (P<0.01).After 3 hours, ASA+CLOP decreased PD by 55%, S18886 by 40%, CLOP alone by 28% (P<0.05), and ASA showed no inhibition versus placebo. Similar effects were found in S18886– and ASA+CLOP-treated animals at both times. Fibrin(ogen) deposition followed the same pattern. Collagen-induced LTA was significantly reduced by ASA, ASA+CLOP, and S18886; S18886 abolished U46619-induced LTA; and, CLOP±ASA reduced ADP-induced LTA in a time-dependent manner. TPr blockade did not prolong BT, whereas CLOP±ASA significantly did (P<0.0001). In conclusion, blockade of theTPr provided a fast and potent platelet inhibitory effect in a porcine model of in-stent thrombosis comparable to that of blocking both the ADP receptor and cyclooxygenase activation; in addition,TPr provided a more favorable bleeding risk profile.

You may also be interested in...

1.
Mariann Gyöngyösi 1, Christoph Strehblow 1, Wolfgang Sperker 1, Akos Hevesi 2, Rita Garamvölgyi 2, Zsolt Petrási 2, Noemi Pavo 1, Péter Ferdinandy 3, Csaba Csonka 3, Tamás Csont 3, Christer Sylvén 4, Paul J. Declerck 5, Imre Pavo Jr 1, Johann Wo

Thromb Haemost 2006 96 2: 202-209

http://dx.doi.org/10.1160/TH06-03-0178

2.

O. Pankiw-Bembenek (1), J. Zalewski (1, 2), T. Goralczyk (1), A. Undas (2, 1)

Thromb Haemost 2012 107 3: 513-520

http://dx.doi.org/10.1160/TH11-09-0662

3.
Sasidhar Guthikonda1, Kirankumar Mangalpally1, Muthiah Vaduganathan1, Rajnikant Patel2, Timothy DeLao1, Angela L. Bergeron3, Jing-Fei Dong3, Eli I. Lev1, Neal S. Kleiman1

Thromb Haemost 2008 100 1: 83-89

http://dx.doi.org/10.1160/TH07-10-0590